Limits...
Invariant NKT cells are resistant to circulating CD15+ myeloid-derived suppressor cells in patients with head and neck cancer.

Horinaka A, Sakurai D, Ihara F, Makita Y, Kunii N, Motohashi S, Nakayama T, Okamoto Y - Cancer Sci. (2016)

Bottom Line: However, the effect on the host immune system, especially on invariant NKT (iNKT) cells with potent anti-tumor activity, remains unclear.However, iNKT cell activation upon α-galactosylceramide (αGalCer) stimulation was not affected by the presence or absence of CD15+ G-MDSC.Cancer immunotherapy designed to enhance the antitumor activity of iNKT cells by stimulation with αGalCer may remain effective in the presence of G-MDSC.

View Article: PubMed Central - PubMed

Affiliation: Department of Otorhinolaryngology, Head and Neck Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan.

Show MeSH

Related in: MedlinePlus

Association of myeloid‐derived suppressor cells subsets with clinical stage and prognosis in head and neck squamous cell carcinoma (HNSCC) patients. (a–d) The percentages of monocytic‐myeloid‐derived suppressor cells (M‐MDSC), granulocytic‐myeloid‐derived suppressor cells (G‐MDSC), CD3+ cells and invariant NKT (iNKT) cells from healthy donors and patients with HNSCC with stage I/II and stage III/IV. The rate of survival between high (>3%) and low (<3%) percentages of M‐MDSC in all stages (e) and stage III/IV (f). The rate of survival between high (>1%) and low (<1%) percentages of G‐MDSC in all stages (g) and stage III/IV (h). *P < 0.05. **P < 0.01.
© Copyright Policy - creativeCommonsBy-nc-nd
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4814259&req=5

cas12866-fig-0004: Association of myeloid‐derived suppressor cells subsets with clinical stage and prognosis in head and neck squamous cell carcinoma (HNSCC) patients. (a–d) The percentages of monocytic‐myeloid‐derived suppressor cells (M‐MDSC), granulocytic‐myeloid‐derived suppressor cells (G‐MDSC), CD3+ cells and invariant NKT (iNKT) cells from healthy donors and patients with HNSCC with stage I/II and stage III/IV. The rate of survival between high (>3%) and low (<3%) percentages of M‐MDSC in all stages (e) and stage III/IV (f). The rate of survival between high (>1%) and low (<1%) percentages of G‐MDSC in all stages (g) and stage III/IV (h). *P < 0.05. **P < 0.01.

Mentions: The association of tumor differentiation and clinical stage of HNSCC with the ratio of G‐MDSC, M‐MDSC and CD3+ cells in PBC before treatment were analyzed in a total of 32 patients with HNSCC. There were no significant differences in the percentage of G‐MDSC, M‐MDSC and CD3+ cell in the pathological differentiation (Table 2). The percentage of G‐MDSC was significantly higher in patients with advanced stage III/IV compared with those with stage I/II (Fig. 4b), but not in M‐MDSC (Fig. 4a). There were no significant differences in CD3+ cells between the clinical stages (Fig. 4c). The percentage of iNKT cells in HNSCC patients was not decreased compared with healthy donors (Fig. 4d). The overall survival rate in the HNSCC patients with increased M‐MDSC (>3%) were not significantly different compared with those of patients with normal numbers of M‐MDSC in all stages (Fig. 4e), stage III/IV (Fig. 4f) or stage IV (data not shown). However, the overall survival rate in HNSCC patients with increased G‐MDSC (>1%) was significantly lower compared with survival of patients with normal levels of G‐MDSC in all stages (Fig. 4g), stage III/IV (Fig. 4h) and stage IV (data not shown).


Invariant NKT cells are resistant to circulating CD15+ myeloid-derived suppressor cells in patients with head and neck cancer.

Horinaka A, Sakurai D, Ihara F, Makita Y, Kunii N, Motohashi S, Nakayama T, Okamoto Y - Cancer Sci. (2016)

Association of myeloid‐derived suppressor cells subsets with clinical stage and prognosis in head and neck squamous cell carcinoma (HNSCC) patients. (a–d) The percentages of monocytic‐myeloid‐derived suppressor cells (M‐MDSC), granulocytic‐myeloid‐derived suppressor cells (G‐MDSC), CD3+ cells and invariant NKT (iNKT) cells from healthy donors and patients with HNSCC with stage I/II and stage III/IV. The rate of survival between high (>3%) and low (<3%) percentages of M‐MDSC in all stages (e) and stage III/IV (f). The rate of survival between high (>1%) and low (<1%) percentages of G‐MDSC in all stages (g) and stage III/IV (h). *P < 0.05. **P < 0.01.
© Copyright Policy - creativeCommonsBy-nc-nd
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4814259&req=5

cas12866-fig-0004: Association of myeloid‐derived suppressor cells subsets with clinical stage and prognosis in head and neck squamous cell carcinoma (HNSCC) patients. (a–d) The percentages of monocytic‐myeloid‐derived suppressor cells (M‐MDSC), granulocytic‐myeloid‐derived suppressor cells (G‐MDSC), CD3+ cells and invariant NKT (iNKT) cells from healthy donors and patients with HNSCC with stage I/II and stage III/IV. The rate of survival between high (>3%) and low (<3%) percentages of M‐MDSC in all stages (e) and stage III/IV (f). The rate of survival between high (>1%) and low (<1%) percentages of G‐MDSC in all stages (g) and stage III/IV (h). *P < 0.05. **P < 0.01.
Mentions: The association of tumor differentiation and clinical stage of HNSCC with the ratio of G‐MDSC, M‐MDSC and CD3+ cells in PBC before treatment were analyzed in a total of 32 patients with HNSCC. There were no significant differences in the percentage of G‐MDSC, M‐MDSC and CD3+ cell in the pathological differentiation (Table 2). The percentage of G‐MDSC was significantly higher in patients with advanced stage III/IV compared with those with stage I/II (Fig. 4b), but not in M‐MDSC (Fig. 4a). There were no significant differences in CD3+ cells between the clinical stages (Fig. 4c). The percentage of iNKT cells in HNSCC patients was not decreased compared with healthy donors (Fig. 4d). The overall survival rate in the HNSCC patients with increased M‐MDSC (>3%) were not significantly different compared with those of patients with normal numbers of M‐MDSC in all stages (Fig. 4e), stage III/IV (Fig. 4f) or stage IV (data not shown). However, the overall survival rate in HNSCC patients with increased G‐MDSC (>1%) was significantly lower compared with survival of patients with normal levels of G‐MDSC in all stages (Fig. 4g), stage III/IV (Fig. 4h) and stage IV (data not shown).

Bottom Line: However, the effect on the host immune system, especially on invariant NKT (iNKT) cells with potent anti-tumor activity, remains unclear.However, iNKT cell activation upon α-galactosylceramide (αGalCer) stimulation was not affected by the presence or absence of CD15+ G-MDSC.Cancer immunotherapy designed to enhance the antitumor activity of iNKT cells by stimulation with αGalCer may remain effective in the presence of G-MDSC.

View Article: PubMed Central - PubMed

Affiliation: Department of Otorhinolaryngology, Head and Neck Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan.

Show MeSH
Related in: MedlinePlus